<DOC>
	<DOCNO>NCT00014300</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness glufosfamide treat patient recurrent glioblastoma multiforme .</brief_summary>
	<brief_title>Glufosfamide Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Determine activity glufosfamide , term objective response rate and/or progression-free survival 6 month , patient recurrent glioblastoma multiforme . II . Determine duration objective response patient treat regimen . III . Determine toxic effect pharmacokinetic profile regimen patient . OUTLINE : This multicenter study . Patients receive glufosfamide IV 60 minute day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients stable disease receive treatment minimum 6 month progression . Patients objective complete response receive maximum 2 additional course treatment confirmation response . Patients follow every 6 week progression . PROJECTED ACCRUAL : A total 28 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm glioblastoma multiforme Recurrent disease CT scan MRI At least 1 bidimensionally measurable target lesion least 2 cm large diameter PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN AST ALT great 2.5 time ULN Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : Cardiac function normal No history ischemic heart disease within past 6 month 12 lead ECG normal Other : No prior concurrent malignancy except cone biopsied cervical cancer adequately treat basal cell squamous cell skin cancer No unstable systemic disease No active uncontrolled infection No psychological , familial , sociological , geographical condition would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic growth factor ( e.g. , filgrastim ( GCSF ) ) Chemotherapy : No 1 prior chemotherapy regimen adjuvant therapy recurrent disease At least 6 week since prior chemotherapy Endocrine therapy : Stable decrease dose corticosteroid least 1 week prior study Radiotherapy : At least 3 month since prior radiotherapy brain No prior highdose radiotherapy ( 65 Gy ) , stereotactic radiosurgery , internal radiotherapy unless disease recurrence histologically confirm Surgery : No prior surgery ( except biopsy ) recurrent brain tumor At least 3 month since prior surgery primary brain tumor Other : No concurrent anticancer agents No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>